Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach
Authors:ID Zupančič, Klemen (Author)
ID Koršič, Marjan (Author)
ID Verbovšek, Urška (Author)
ID Rožman, Primož (Author)
ID Lah Turnšek, Tamara (Author)
ID Blejec, Andrej (Author)
ID Gruden, Kristina (Author)
ID Motaln, Helena (Author)
ID Knežević, Miomir (Author)
ID Veber, Matija (Author)
ID Herman, Ana (Author)
Files:URL URL - Presentation file, visit http://www.degruyter.com/view/j/raon.2014.48.issue-3/raon-2014-0014/raon-2014-0014.xml?format=INT
 
.pdf PDF - Presentation file, download (621,07 KB)
MD5: D30E197A64963B5C4830441C4E10EECD
 
URL URL - Source URL, visit https://doi.org/10.2478/raon-2014-0014
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo NIB - National Institute of Biology
Abstract:Background. Glioblastoma multiforme (GBM) is a brain tumour with a very high patient mortality rate, with a median survival of 47 weeks. This might be improved by the identification of novel diagnostic, prognostic and predictive therapy-response biomarkers, preferentially through the monitoring of the patient blood. The aim of this study was to define the impact of GBM in terms of alterations of the plasma protein levels in these patients. Materials and methods. We used a commercially available antibody array that includes 656 antibodies to analyse blood plasma samples from 17 healthy volunteers in comparison with 17 blood plasma samples from patients with GBM. Results. We identified 11 plasma proteins that are statistically most strongly associated with the presence of GBM. These proteins belong to three functional signalling pathways: T-cell signalling and immune responses; cell adhesion and migration; and cell-cycle control and apoptosis. Thus, we can consider this identified set of proteins as potential diagnostic biomarker candidates for GBM. In addition, a set of 16 plasma proteins were significantly associated with the overall survival of these patients with GBM. Guanine nucleotide binding protein alpha (GNAO1) was associated with both GBM presence and survival of patients with GBM. Conclusions. Antibody array analysis represents a useful tool for the screening of plasma samples for potential cancer biomarker candidates in small-scale exploratory experiments; however, clinical validation of these candidates requires their further evaluation in a larger study on an independent cohort of patients.
Keywords:glioblastoma, proteomics, biomarker
Publication status:Published
Publication version:Version of Record
Publication date:04.12.2014
Year of publishing:2014
Number of pages:str. 257-266, III
Numbering:Vol. 48, no. 3
PID:20.500.12556/DiRROS-5185 New window
ISSN:1318-2099
UDC:616.831-006-07
DOI:10.2478/raon-2014-0014 New window
COBISS.SI-ID:31525081 New window
Publication date in DiRROS:02.08.2024
Views:12
Downloads:6
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Document is financed by a project

Funder:Other - Other funder or multiple funders
Project number:3211-06-000539
Name:Systems Biology Tools Development for Cell Therapy and Drug Development
Acronym:SYSTHER/ INREMOS project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0245
Name:Ekotoksiologija, toksikološka genomika in karcinogeneza

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:MR09/27

Secondary language

Language:Slovenian
Keywords:glioblastom, proteomika, biomarker


Back